Abstract:The use of reverse transcription-PCR (RT-PCR) to analyze cells in the blood of cancer patients for the detection of mRNA expressed in tumor cells has implications for both the prognosis and the monitoring of cancer patients for the efficacy of established or experimental therapies. Carcinoembryonic antigen (CEA) is expressed on approximately 95% of colorectal, gastric, and pancreatic tumors, and on the majority of breast, non-small cell lung, and head and neck carcinomas. CEA shed in serum is useful as a marker in only approximately 50% of colorectal cancer patients and rarely is shed by some other carcinoma types. RT-PCR has been used previously to detect CEA mRNA in cells in the blood and lymph nodes of cancer patients. Under the assay conditions validated in the studies reported here, 34 of 51 (67%) patients with different stages of colorectal cancer had blood cells that were positive by RT-PCR for CEA mRNA, whereas none of 18 patients with colonic polyps were positive; 2 of 60 apparently healthy individuals (who were age and sex matched with the carcinoma patients and were part of a colon cancer screening program as controls) were marginally positive. The results of CEA PCR in the blood of the carcinoma patients and the other groups showed strong statistical correlation with the disease (P2 < 0.0001). Analyses were carried out to detect both serum CEA protein levels and CEA mRNA in blood cells of colorectal carcinoma patients by RT-PCR. For all stages of disease, 18 of 51 patients (35%) were positive for serum CEA, whereas 35 of 51 (69%) were positive by RT-PCR. More importantly, only 5 of 23 (20%) of stage B and C colorectal cancer patients were positive for serum CEA, whereas 16 of 23 (70%) were positive by RT-PCR. The use of two other serum markers (CA19.9 and CA72-4) for colorectal cancer in combination with serum CEA scored two additional patients as positive; both were positive by RT-PCR for CEA mRNA. Pilot long-term longitudinal studies conducted before and after surgery identified some patients with CEA mRNA in blood cells that were negative for all serum markers, who eventually developed clinical metastatic disease. The studies reported here are the first to correlate RT-PCR results for CEA mRNA in blood cells with one or more serum markers for patients with different stages of colorectal cancer, and are the first long-term longitudinal studies to use RT-PCR to detect CEA mRNA in blood cells of cancer patients. Larger cohorts will be required in future studies to define the impact, if any, of this technology on prognosis and/or disease monitoring.

Quantitative Real-Time RT-PCR Detection for CEA, CK20 and CK19 Mrna in Peripheral Blood of Colorectal Cancer Patients.

Quantitative Real-Time Rt-Pcr Detection For Survivin, Ck20 And Cea In Peripheral Blood Of Colorectal Cancer Patients

Significance of CK20 Mrna Expression in Peripheral Blood of Colorectal Cancer Patients by Real-Time Fluorescent Quantitative RT-PCR

Clinical Significance of CK20, CK19, CEA Mrnas in Peripheral Blood from Lung Cancer Patients

Quantitative Detection of Disseminated Cancer Cells in Peritoneal Washes with Real-Time RT-PCR for Patients with Colorectal Carcinoma and Its Clinical Significance

Molecular detection of disseminated tumor cells in the peripheral blood in patients with gastrointestinal cancer

Quantitative detection of CEA level in the peritoneal cavity of colorectal carcinoma patients with real-time RT-PCR and Its clinical significance

Clinical significance of CEA and CK20 expression in exfoliated cells by fiberoptic bronchoscopy brushing

Significance of Detecting Disseminated Tumor Cells in Peripheral Blood of Patients with Colorectal Carcinoma

Detection and Clinicopathologic Significance of CK20,CK19,CEA Mrna in Peripheral Blood from Patients with Esophageal Cancer

[Combined Detection of CEA Mrna and CK 19 Mrna in Peripheral Blood Cells of Patients with Lung Cancer].

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

Detection of CEA Mrna and HNP1-3 in Peripheral Blood of Patients with Colorectal Cancer and Its Clinical Significance

The Clinical Value of CEA Mrna、cea Protein of Peripheral Blood in the Prediction of Colorectal Cancer

Molecular Detection of Disseminated Tumor Cells in the Peripheral Blood of Patients with Gastric Cancer: Evaluation of Their Prognostic Significance

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers

Significance of Peripheral Blood CEA mRNA and livin mRNA in Combined Detection of Micro Metastases in Colorectal Cancer Patients

Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer

Study of CEA Mrna Expression in Cancer and Lymph Nodes Tissues with SYBR Green I Real-Time Quantitative Polymerase Chain Reaction

Clinical Significance of the Expression of CK20 Mrna in Portal Vein Blood of Patients with Colorectal Cancer During Operation

Study of Cytokeratin 20 Expression and p53 Gene Mutation in Peripheral Blood of Patients with Colorectal Carcinoma